PT  - JOURNAL ARTICLE
AU  - PASQUALETTI, FRANCESCO
AU  - GONNELLI, ALESSANDRA
AU  - MOLINARI, ALESSANDRO
AU  - CANTARELLA, MARTINA
AU  - MONTRONE, SABRINA
AU  - CRISTAUDO, AGOSTINO
AU  - BALDACCINI, DAVIDE
AU  - MATTIONI, ROBERTO
AU  - DELISHAJ, DURIM
AU  - MAZZOTTI, VALENTINA
AU  - MORGANTI, RICCARDO
AU  - COCUZZA, PAOLA
AU  - FABRINI, MARIA GRAZIA
AU  - LOMBARDI, GIUSEPPE
AU  - RUDÀ, ROBERTA
AU  - SOFFIETTI, RICCARDO
AU  - PAIAR, FABIOLA
TI  - Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early <em>Versus</em> Delayed Administration
AID  - 10.21873/anticanres.12930
DP  - 2018 Oct 01
TA  - Anticancer Research
PG  - 5877--5881
VI  - 38
IP  - 10
4099  - http://ar.iiarjournals.org/content/38/10/5877.short
4100  - http://ar.iiarjournals.org/content/38/10/5877.full
SO  - Anticancer Res2018 Oct 01; 38
AB  - Background/Aim: In patients with recurrent glioblastoma, the best timing to administer bevacizumab is not well addressed yet. In this study, we reported the results of a monocentric experience comparing the early use of bevacizumab (following the first GBM recurrence) with the delayed administration (following the second or even further GBM recurrences). Materials and Methods: This analysis included 129 glioblastoma patients with a median follow-up of 22.4 months (range=5.26-192 months). Results: The median time lapse from diagnosis of glioblastoma to disease recurrence was 11.6 months; 13.1 for patients treated with deferred administration of bevacizumab and 9.9 for patients with early administration (p=0.047). Bevacizumab progression-free survival with early and delayed use was 3.45 and 2.92 months, respectively (p=0.504). Survival time from the start of bevacizumab was 6.18 months in patients with early administration, and 6.47 in the delayed administration one (p=0.318). Conclusion: Delayed administration of bevacizumab can be considered in selected patients with less aggressive recurrent glioblastoma.